Sign In
Buy RVPH
$0.695
+0.0350 (+5.30%)
At Close: Jun 23, 2026
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
08:00am, Tuesday, 23'rd Jun 2026
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
08:00am, Monday, 18'th May 2026
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company deve
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
04:35pm, Wednesday, 13'th May 2026
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts
02:21am, Monday, 06'th Apr 2026
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat reports
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
06:05am, Monday, 30'th Mar 2026
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –
What's Behind The Drop In Reviva Pharmaceuticals Stock?
12:49pm, Thursday, 19'th Mar 2026
According to an SEC filing from Wednesday, Reviva will sell 6,666,667 common shares priced at $1.50 each, a move that will raise more than $10 million for the company.
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
10:34pm, Wednesday, 18'th Mar 2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
04:10pm, Wednesday, 18'th Mar 2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
08:00am, Monday, 29'th Dec 2025
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Moderate Buy” by Analysts
02:30am, Saturday, 27'th Dec 2025
Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the co
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
09:26am, Tuesday, 23'rd Dec 2025
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
08:00am, Tuesday, 23'rd Dec 2025
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the t
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Thursday, 13'th Nov 2025
– Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – �
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Rises By 60.7%
02:49am, Tuesday, 04'th Nov 2025
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totaling 22,270,00
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
